The implication of these findings is that the response to androgen stimulation by benign/malignant prostate tissues, and response to androgen deprivation therapy (ADT) of benign/prostate cancer tissues, needs to be evaluated separately in the different cell types due to the presence of different cell type-specific AR signaling networks. This evidence concerns the gene AR and Familial prostate cancer.